Propanc Biopharma, Inc. (PPCB)
2.115
0.00 (0.00%)
USD |
NASDAQ |
Oct 29, 16:00
2.115
0.00 (0.00%)
After-Hours: 16:40
Propanc Biopharma Enterprise Value : 6.663M for Oct. 28, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 28, 2026 | 6.663M |
| October 27, 2026 | 7.722M |
| October 26, 2026 | 7.259M |
| October 23, 2026 | 8.947M |
| October 22, 2026 | 8.749M |
| October 21, 2026 | 10.12M |
| October 20, 2026 | 10.30M |
| October 19, 2026 | 0.7266M |
| October 16, 2026 | 0.8094M |
| October 15, 2026 | 0.8077M |
| October 14, 2026 | 0.8879M |
| October 13, 2026 | 1.043M |
| October 12, 2026 | 1.134M |
| October 09, 2026 | 1.285M |
| October 08, 2026 | 1.236M |
| October 07, 2026 | 1.328M |
| October 06, 2026 | 1.304M |
| October 05, 2026 | 1.332M |
| October 02, 2026 | 1.357M |
| October 01, 2026 | 1.336M |
| September 30, 2026 | 1.313M |
| September 29, 2026 | 1.373M |
| September 28, 2026 | 1.443M |
| September 25, 2026 | 1.764M |
| September 24, 2026 | 1.670M |
| Date | Value |
|---|---|
| September 23, 2026 | 1.756M |
| September 22, 2026 | 1.832M |
| September 21, 2026 | 1.762M |
| September 18, 2026 | 1.697M |
| September 17, 2026 | 1.763M |
| September 16, 2026 | 1.780M |
| September 15, 2026 | 2.392M |
| September 14, 2026 | 2.491M |
| September 11, 2026 | 2.726M |
| September 10, 2026 | 2.798M |
| September 09, 2026 | 2.955M |
| September 08, 2026 | 3.087M |
| September 04, 2026 | 3.021M |
| September 03, 2026 | 3.054M |
| September 02, 2026 | 3.087M |
| September 01, 2026 | 3.418M |
| August 31, 2026 | 4.147M |
| August 28, 2026 | 4.147M |
| August 27, 2026 | 7.060M |
| August 26, 2026 | 3.220M |
| August 25, 2026 | 3.418M |
| August 24, 2026 | 3.501M |
| August 21, 2026 | 3.253M |
| August 20, 2026 | 3.319M |
| August 19, 2026 | 3.451M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Immutep Ltd. | -- |
| CSL Ltd. | -- |
| Ceryvyn Therapeutics Ltd. | -- |
| Mesoblast Ltd. | 1.781B |
| Actinogen Medical Ltd. | -- |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.573M |
| Total Expenses (Quarterly) | 4.573M |
| EPS Diluted (Quarterly) | -1.381 |
| Earnings Yield | -1.22K% |
| Normalized Earnings Yield | -1263.70 |